252.2

-0.24%↓

SAN

81.53

+0.6%↑

SHL.DE

45.86

-1.27%↓

ARGX

552.4

-3.16%↓

PHIA

22.97

-0.17%↓

252.2

-0.24%↓

SAN

81.53

+0.6%↑

SHL.DE

45.86

-1.27%↓

ARGX

552.4

-3.16%↓

PHIA

22.97

-0.17%↓

252.2

-0.24%↓

SAN

81.53

+0.6%↑

SHL.DE

45.86

-1.27%↓

ARGX

552.4

-3.16%↓

PHIA

22.97

-0.17%↓

252.2

-0.24%↓

SAN

81.53

+0.6%↑

SHL.DE

45.86

-1.27%↓

ARGX

552.4

-3.16%↓

PHIA

22.97

-0.17%↓

252.2

-0.24%↓

SAN

81.53

+0.6%↑

SHL.DE

45.86

-1.27%↓

ARGX

552.4

-3.16%↓

PHIA

22.97

-0.17%↓

Kodu・Aktsiate loetelu・Pharming Group NV

P
Pharming Group NV

Avatud

1.012 -0.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.003

Max

1.037

Põhinäitajad
By Trading Economics
Sissetulek	19M 4.7M
Müük	14M 93M
Aktsiakasum	-0.02
Kasumimarginaal	5.035
Töötajad	404

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+68.95% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	81M 699M
Eelmine avamishind	1.99
Eelmine sulgemishind	1.012

Pharming Group NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. aug 2025, 21:43 UTC

Tulu

Constellation Software 2Q Revenue Rises, Profit Shrinks

10. aug 2025, 23:54 UTC

Market Talk

Gold Edges Lower Amid Mixed Signals on Possible U.S. Tariffs -- Market Talk

10. aug 2025, 23:51 UTC

Market Talk

China's July Data Could Confirm Weakening Momentum -- Market Talk

10. aug 2025, 23:38 UTC

Market Talk

Oil Falls Amid Easing Supply-Disruption Concerns -- Market Talk

10. aug 2025, 23:29 UTC

Market Talk

RBA Board Meeting Still Has Some Uncertainty -- Market Talk

10. aug 2025, 23:14 UTC

Market Talk

RBA's Communication With Markets in Spotlight -- Market Talk

10. aug 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Confirms Hasn't Discovered Anything That Would Cause Withdrawal of Indicative Proposal

10. aug 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Santos: Decision to Allow XRG Consortium to Finalize Due Diligence, Progress Scheme Implementation Agreement

10. aug 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

Santos Extends Exclusivity Period for XRG Consortium to August 22

10. aug 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Santos Extends Exclusivity Period for XRG Consortium

10. aug 2025, 22:55 UTC

Market Talk

Australian Inflation Expectations Continue to Fall -- Market Talk

10. aug 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Spark NZ Says Process to Seek Capital Partner for Data Center Business Ongoing

9. aug 2025, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

9. aug 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. aug 2025, 22:42 UTC

Omandamised, ülevõtmised, äriostud

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8. aug 2025, 21:31 UTC

Market Talk

Tulu

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q Rev $2.84B >CSU.T

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q Net $56M >CSU.T

8. aug 2025, 21:00 UTC

Tulu

Constellation Software 2Q EPS $2.66 >CSU.T

8. aug 2025, 20:55 UTC

Market Talk

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8. aug 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

8. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. aug 2025, 20:35 UTC

Market Talk

Mexico's Industrial Production Seen Higher in June -- Market Talk

8. aug 2025, 20:28 UTC

Tulu

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8. aug 2025, 20:28 UTC

Tulu

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8. aug 2025, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8. aug 2025, 20:08 UTC

Tulu

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8. aug 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8. aug 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8. aug 2025, 19:13 UTC

Market Talk

Oil Futures End Volatile Week Lower -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pharming Group NV Prognoos

Hinnasiht

By TipRanks

68.95% tõus

12 kuu keskmine prognoos

Keskmine 1.723 EUR 68.95%

Kõrge 2.45 EUR

Madal 1 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Pharming Group NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pharming Group NV aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.